Home Cost management

Keyword: Cost management

169 results found

Average benefits costs for U.S. employers will increase 6.5 per cent — or more than $13,800 per employee — in 2023, according to a new report by Aon. This projection is more than double the three per cent increase to health-care budgets from 2021 to 2022, but below the 9.1 inflation figure reported through the consumer price […]

  • By: Staff
  • August 24, 2022 August 23, 2022
  • 09:00

U.S. employers are anticipating health benefits costs will rise by an average of 5.6 per cent per employee in 2023, according to early results from a survey by Mercer. The survey, which polled more than 850 U.S. employers, found if respondents made no changes to their benefits plans, the cost for the largest plans would rise […]

  • By: Staff
  • August 16, 2022 August 15, 2022
  • 09:00

The drug pipeline is full of new medications that may be more effective but may also be more expensive than existing treatments. Although they could significantly improve a benefits plan member’s health, they could also render a plan unaffordable. “Because drugs represent a significant portion of group insurance plan costs, plan sponsors are concerned about […]

Employer-provided medical benefits costs in Canada will rise seven per cent in 2022, according to a new survey by Aon. The annual global medical trend rates survey found the expected increase for Canadian employer-sponsored medical plan costs is due to a combination of higher costs for dental care, paramedical expenses and prescription drugs. It was conducted […]

  • By: Staff
  • October 13, 2021 October 13, 2021
  • 09:00
118722682_l-1

The Nova Scotia Teachers’ Pension Plan returned 6.78 per cent in 2020, increasing net assets to $5.519 billion, but falling short of the policy benchmark of 7.96 per cent. The plan did outperform the actuarial assumed rate of return of 5.70 per cent.  “Like many pension plans across the country impacted by COVID-19, we saw […]

Drug pricing reforms may impact Canadians’ access to medications

Despite concerns Canadian drug prices are skyrocketing, the Patented Medicines Price Review Board, Canada’s price regulator, has ensured costs for patented drugs haven’t increased more than the Canadian Consumer Price Index in close to 30 years, said Wayne Critchley, Global Public Affairs’ senior associate of health and life sciences, during Benefits Canada’s Face to Face […]

A recent Telus Health comparison of a drug’s cost effectiveness when calculated from the private versus the public-payer perspective demonstrated clearly that the private-payer perspective matters when assessing the value of a medication, explained Dr Nina Lathia, pharmacist, and health economist, at Benefits Canada’s Face to Face Drug Plan Management Forum on Dec. 9, 2020. […]

Specialty drug prior authorization a useful tool for plan sponsors

Analysis by Telus Health found specialty drugs have grown from 11 per cent of total private drug plan claims costs in 2008 to 30 per cent in 2019 and require effective management to ensure sustainability of health benefits plans, said Suzanne Lepage, private health plan strategist, during a session at Benefits Canada’s Face to Face […]

Employers balancing benefits costs and employee well-being: survey

As the coronavirus pandemic continues, Canadian employers are balancing the need to reduce benefits costs while focusing on employee well-being, according to a new survey by Arthur J. Gallagher & Co. Just over half (55 per cent) of respondents said controlling costs is their top benefits-related challenge this year, with many considering measures such as variable cost […]

  • By: Staff
  • November 25, 2020 November 25, 2020
  • 08:30
Group health plan costs expected to rise in 2021: report

The costs of employer-provided health plans in Canada are expected to rise seven per cent next year, outpacing general inflation by more than five per cent, according to a new report by Aon Canada. Contributing factors include higher drug prices, the impact of non-communicable health risks and the continued introduction of new and expensive therapies. Indeed, […]

  • By: Staff
  • October 29, 2020 October 29, 2020
  • 15:15